Connect with us

Spread & Containment

RNA Medicines Address Stability and Deliverability Challenges

Some are saying that mRNA medicines—mRNA vaccines and mRNA therapeutics alike—will open a golden era of medicine. And the enthusiasm is catching. Following…

Published

on

Some are saying that mRNA medicines—mRNA vaccines and mRNA therapeutics alike—will open a golden era of medicine. And the enthusiasm is catching. Following the precedent set by the first mRNA-based COVID-19 vaccines, hundreds of new mRNA medicines are moving through development pipelines. More than 300 disease indications are being targeted.

The unprecedented speed, versatility, and effectiveness of mRNA vaccines has prompted a rapid expansion of the technology targeting many more infectious diseases, as well as new treatments that fight cancer and treatments that replace proteins that are absent or dysfunctional due to genetic mutations.

To learn more about the current status and near-term potential of mRNA medicines, GEN invited several leaders in the field to share their perspectives. They responded by highlighting the field’s current challenges and most promising solutions. Most important, they shared their predictions about the field’s exciting future.

Successes and gaps

The initial mRNA-based vaccines for targeting SARS-CoV-2 undoubtedly represented a “stellar achievement,” says Helen O. McCarthy, PhD, professor of nanomedicine, School of Pharmacy, Queen’s University Belfast. “[They] demonstrated that the human immune system could be trained to recognize and mount an immune response for preventing infection or reducing the symptoms. This has led to a pipeline of prophylactic vaccines for other diseases of concern which includes, but is not limited to, influenza, respiratory syncytial virus, Zika, Nipah, monkeypox, malaria, and HIV. This illustrates the impact that mRNA technology is having.”

Helen O. McCarthy, PhD
Queen’s University, Belfast

According to McCarthy, the clinical pipeline looks very promising for a number of other applications: “Clinical mRNA trials also include a host of other indications. They include asthma, cystic fibrosis, chronic obstructive pulmonary disease, muscular dystrophies, and epidermolysis bullosa. All of these really demonstrate the opportunities with this technology.”

However, McCarthy points out that some significant challenges remain. One example she cites is delivery. “The delivery system … must ensure that the mRNA is shuttled inside the cell,” she explains. “That is, mRNA translation into vaccine antigens or therapeutic proteins happens only after cytoplasmic delivery. For this to happen, the mRNA must be packed into nanoparticles that fall within a range capable of entering the cell, predominantly via endocytosis. To date, the lipid nanoparticle (LNP) technologies have been tremendously successful in doing this, but there is always room to improve.”

McCarthy’s research focuses on the use of peptides to deliver nucleic acids. “These peptides are composed of natural amino acids and are designed to condense the mRNA into nanoparticles that enter cells and escape endosomes without the cell recognizing this as foreign,” she details. “This enables multiple administrations without provoking antipeptide antibodies. The peptide nanoparticles do not circulate for long periods of time and enter cells quickly.”

According to McCarthy, the use of peptides has several other important advantages: “The peptides are not restricted as to the size of nucleic acid with which they can complex, as this is based upon charge. Furthermore, they can be lyophilized and stored at room temperature.”

There are other applications of this technology. “Apart from both prophylactic and therapeutic vaccines, we are also incorporating these nanoparticles into injectable hydrogels for bone repair, along with 3D-printed and electrospun devices for wound healing,” McCarthy relates. “Our current work is particularly focused on a novel targeted delivery platform for mRNA.”

Inhaled therapeutics

“Beyond vaccines, we’re now looking toward mRNA’s use in therapeutics and opening additional routes of delivery beyond intravenous administration, including nebulization and nasal sprays for inhaled delivery,” reports Carsten Rudolph, PhD, the CEO of Ethris. “In the near future, inhaled mRNA therapies have the potential to treat chronic or genetic diseases of the lung, such as chronic obstructive pulmonary disease, primary ciliary dyskinesia, and pulmonary alveolar proteinosis.”

However, Rudolph points out that the field still has problems that need solutions, several of which are being pursued by Ethris. “Despite the potential of inhaled mRNA therapeutics, the mechanical and thermal instability of LNP-delivered mRNA therapeutics presents a challenge,” he says. “When creating these medicines, we knew, right off the bat, that we had to overcome the challenge of LNP aggregation during nebulization. Such aggregation can hinder delivery, potentially lengthening application times, triggering immune responses, and jeopardizing treatment effectiveness. Another challenge is mRNA’s inherent immunogenicity, potentially causing unwanted inflammation or responses against the therapy. Yet another challenge is the vulnerability of mRNA itself to degradation.”

Carsten Rudolph,
Carsten Rudolph, PhD
Ethris

According to Rudolph, Ethris has developed a suite of proprietary technology platforms for improving the precision of delivery, the stability of RNA, and the efficacy of treatment. He adds, “We’ve also made a number of improvements in the manufacturing process for mRNA medicines.”

Specifically, Ethris’ SNaP lipidoid LNP platform tackles therapeutic potency and delivery of mRNA by better retention of the therapeutic payload locally at the site of administration. “The therapies have precise exposure at the target site,” Rudolph asserts. “Unlike current commercial mRNA vaccines, they don’t show up where they are not desired, that is, in tissues such as the liver, heart, and brain.”

“[The company’s stabilizer technology] allows for extended room temperature storage and handling of mRNA medicines,” he continues. “Additionally, our SNIM RNA technology conquers mRNA’s inherent instability and immunity barriers, with greatly increased tolerability to unmodified mRNA. Notably, it can be repeatedly administered, leading to consistent production of therapeutic proteins within the body.”

Ethris has begun a Phase I study of ETH47 for the treatment and prophylaxis of respiratory viral infections. The company is also applying its inhaled technology in rare lung diseases including primary ciliary dyskinesia, whose symptoms resemble cystic fibrosis and for which there are currently no approved therapies.

InhaledDelivery with Precision Targeting images
Preclinical studies have demonstrated the potential of lipid nanoparticle (LNP) technology employed by Ethris, a developer of RNA-based vaccines and medicines. For example, these studies have shown that Ethris’s Stabilized NanoParticle (SNaP) platform facilitates the inhaled delivery of mRNA-containing LNPs to the respiratory tract. SNaP is one of the technologies behind Ethris’s ETH47, an inhaled mRNA meant to counter respiratory viral infections. It was approved for a Phase I study late last year.

Immunomodulation and beyond

Although vaccines against infectious diseases remain prominent on the mRNA therapeutics radar, other applications are making headway. “Early personalized cancer vaccine data from several RNA companies raises some hopes, although this needs to be confirmed,” says Gilles Besin, PhD, the CSO of Orbital Therapeutics. “Certainly, in vivo treatment using chimeric antigen receptor (CAR) T cells represents an immediate application that can unlock the therapeutic potential of RNA. However, the question of delivery to immune cells is still unresolved. Progress has been made and has encouraged the biotechnology world to exert more effort.”

Gilles Besin
Gilles Besin, PhD
Orbital Therapeutics

Other advancements in cancer therapeutics include the mRNA-driven production of functional proteins to either control tumor progression or modulate (that is, boost) immune responses. Further, mRNA-encoded proteins for genome editing may be able to disrupt tumor survival genes and provide enhanced efficacy of traditional cancer therapies.

Expanding beyond cancer, mRNA-
based therapeutics may also play an important role in the in vivo production of functional proteins that are absent or nonfunctional due to genetic mutations. Besin points out that durability is especially important in this area: “Durable expression allows for less frequent injection and eases the dosing regimens. This could change the life of many patients.”

Besin reports that Orbital’s expression enhancing platform utilizes a closed RNA molecule for increased resistance to exonucleases. “Such circular RNA,” he says, “can extend durability of RNA expression in a cell-dependent manner. In addition, in the vaccine context, circular RNA has been shown to elicit greater T-cell responses.” The company is currently conducting preclinical studies.

Second-generation advances

“The beauty of mRNA technology is that it can continuously be improved,” says Alexander Zehnder, MD, the CEO of CureVac. “Luckily, we are just at the beginning of what’s possible with mRNA.”

Zehnder agrees that delivery of mRNA therapeutics remains a key area where improvement is needed: “As a field, we need to continue to advance LNP technology, which is used for mRNA delivery, to increase the potency, safety, and stability of mRNA therapeutics. Additionally, to expand mRNA’s potential across a broad range of possible indications, advancing LNPs to achieve more precision in tissue targeting will be critical.”

In parallel with delivery, mRNA stability remains another key issue. RNA is a relatively large and inherently unstable molecule prone to degradation by 5¢ and 3¢ exonucleases and endonucleases. Thus, different strategies are being investigated to improve its stability in the delivery process. For example, CureVac customizes the 5¢ and 3¢ untranslated regions and the open reading frames of mRNAs to engineer for greater stability and thus increased translation into protein product.

Alexander Zehnder
Alexander Zehnder, MD
CureVac

“We believe our technology platform is a broad and versatile platform to develop optimized mRNA-based medicines with the potential for a differentiated profile in terms of tolerability, stability, and protein expression,” Zehnder elaborates. “We are currently advancing our second-generation mRNA backbone in prophylactic vaccines as well as oncology.

“This backbone features targeted optimizations for improved intracellular mRNA translation for early and strong immune responses at low doses. In collaboration with GSK, we generated early, positive data from our COVID-19 and seasonal flu mRNA vaccine trials in 2023 to provide validation for our second-generation mRNA technology.”

CureVac is testing two mRNA-based COVID-19 vaccine candidates in a Phase II study, with data expected in early 2024. In addition, the company recently began testing an influenza vaccine candidate in another Phase II study. The candidate performed well in an initial trial, and data is expected in 2024.

Zehnder predicts a bright future for mRNA therapeutics: “Its speed, versatility, and ultimate potential to help patients is a powerhouse combination that will propel mRNA medicines forward.”

Fast translation

“We aim to cut down research time by offering deep insights into the RNA landscape and providing the granular data behind the holistic trends,” says Ioana Panait, a senior RNA research analyst at Beacon, a science database solution for RNA developers. Panait points out that incredible achievements have been made in the RNA field in 2023, and that the fastest-growing part of this field is mRNA therapeutics.

Ioana Panait
Ioana Panait
Beacon

“The data highlights a 29% growth of the preclinical space and 32% growth of the clinical space of mRNA therapeutics in development throughout 2023,” she details. “Over the past year, approximately 250 new mRNA therapies have entered pipelines, while at the same time showing a fast translation into clinical stages.”

Painit expects the field to continue growing: “The potential of mRNA therapeutics is highlighted not only by the number of new therapies being developed or by drug developers entering the field, but also by the diversity of disease indications investigated. Over 300 different disease indications are currently being studied in the space.”

Although Panait also cites delivery of mRNA therapeutics as a challenge needing to be addressed, she indicates some practices are slowing overall progress: “There is an increase of proprietary delivery systems, which can indicate movement in the right direction; however, developers continue to disclose these delivery systems at later stages of drug development, which will contribute to this challenge being harder to overcome. There also is a lack of pharmacokinetic/pharmacodynamic data in the mRNA field, with less than 5% of drugs having preclinical pharmacokinetic/pharmacodynamic data released publicly.”

Despite the remaining challenges, Panait believes that there is cause for great optimism. “The expansion of the mRNA field is no longer surprising,” she declares. “The field is bound to continue growing at a similar pace in the coming years.”

The post RNA Medicines Address Stability and Deliverability Challenges appeared first on GEN - Genetic Engineering and Biotechnology News.

Read More

Continue Reading

Government

Chinese migration to US is nothing new – but the reasons for recent surge at Southern border are

A gloomier economic outlook in China and tightening state control have combined with the influence of social media in encouraging migration.

Published

on

By

Chinese migrants wait for a boat after having walked across the Darien Gap from Colombia to Panama. AP Photo/Natacha Pisarenko

The brief closure of the Darien Gap – a perilous 66-mile jungle journey linking South American and Central America – in February 2024 temporarily halted one of the Western Hemisphere’s busiest migration routes. It also highlighted its importance to a small but growing group of people that depend on that pass to make it to the U.S.: Chinese migrants.

While a record 2.5 million migrants were detained at the United States’ southwestern land border in 2023, only about 37,000 were from China.

I’m a scholar of migration and China. What I find most remarkable in these figures is the speed with which the number of Chinese migrants is growing. Nearly 10 times as many Chinese migrants crossed the southern border in 2023 as in 2022. In December 2023 alone, U.S. Border Patrol officials reported encounters with about 6,000 Chinese migrants, in contrast to the 900 they reported a year earlier in December 2022.

The dramatic uptick is the result of a confluence of factors that range from a slowing Chinese economy and tightening political control by President Xi Jinping to the easy access to online information on Chinese social media about how to make the trip.

Middle-class migrants

Journalists reporting from the border have generalized that Chinese migrants come largely from the self-employed middle class. They are not rich enough to use education or work opportunities as a means of entry, but they can afford to fly across the world.

According to a report from Reuters, in many cases those attempting to make the crossing are small-business owners who saw irreparable damage to their primary or sole source of income due to China’s “zero COVID” policies. The migrants are women, men and, in some cases, children accompanying parents from all over China.

Chinese nationals have long made the journey to the United States seeking economic opportunity or political freedom. Based on recent media interviews with migrants coming by way of South America and the U.S.’s southern border, the increase in numbers seems driven by two factors.

First, the most common path for immigration for Chinese nationals is through a student visa or H1-B visa for skilled workers. But travel restrictions during the early months of the pandemic temporarily stalled migration from China. Immigrant visas are out of reach for many Chinese nationals without family or vocation-based preferences, and tourist visas require a personal interview with a U.S. consulate to gauge the likelihood of the traveler returning to China.

Social media tutorials

Second, with the legal routes for immigration difficult to follow, social media accounts have outlined alternatives for Chinese who feel an urgent need to emigrate. Accounts on Douyin, the TikTok clone available in mainland China, document locations open for visa-free travel by Chinese passport holders. On TikTok itself, migrants could find information on where to cross the border, as well as information about transportation and smugglers, commonly known as “snakeheads,” who are experienced with bringing migrants on the journey north.

With virtual private networks, immigrants can also gather information from U.S. apps such as X, YouTube, Facebook and other sites that are otherwise blocked by Chinese censors.

Inspired by social media posts that both offer practical guides and celebrate the journey, thousands of Chinese migrants have been flying to Ecuador, which allows visa-free travel for Chinese citizens, and then making their way over land to the U.S.-Mexican border.

This journey involves trekking through the Darien Gap, which despite its notoriety as a dangerous crossing has become an increasingly common route for migrants from Venezuela, Colombia and all over the world.

In addition to information about crossing the Darien Gap, these social media posts highlight the best places to cross the border. This has led to a large share of Chinese asylum seekers following the same path to Mexico’s Baja California to cross the border near San Diego.

Chinese migration to US is nothing new

The rapid increase in numbers and the ease of accessing information via social media on their smartphones are new innovations. But there is a longer history of Chinese migration to the U.S. over the southern border – and at the hands of smugglers.

From 1882 to 1943, the United States banned all immigration by male Chinese laborers and most Chinese women. A combination of economic competition and racist concerns about Chinese culture and assimilability ensured that the Chinese would be the first ethnic group to enter the United States illegally.

With legal options for arrival eliminated, some Chinese migrants took advantage of the relative ease of movement between the U.S. and Mexico during those years. While some migrants adopted Mexican names and spoke enough Spanish to pass as migrant workers, others used borrowed identities or paperwork from Chinese people with a right of entry, like U.S.-born citizens. Similarly to what we are seeing today, it was middle- and working-class Chinese who more frequently turned to illegal means. Those with money and education were able to circumvent the law by arriving as students or members of the merchant class, both exceptions to the exclusion law.

Though these Chinese exclusion laws officially ended in 1943, restrictions on migration from Asia continued until Congress revised U.S. immigration law in the Hart-Celler Act in 1965. New priorities for immigrant visas that stressed vocational skills as well as family reunification, alongside then Chinese leader Deng Xiaoping’s policies of “reform and opening,” helped many Chinese migrants make their way legally to the U.S. in the 1980s and 1990s.

Even after the restrictive immigration laws ended, Chinese migrants without the education or family connections often needed for U.S. visas continued to take dangerous routes with the help of “snakeheads.”

One notorious incident occurred in 1993, when a ship called the Golden Venture ran aground near New York, resulting in the drowning deaths of 10 Chinese migrants and the arrest and conviction of the snakeheads attempting to smuggle hundreds of Chinese migrants into the United States.

Existing tensions

Though there is plenty of precedent for Chinese migrants arriving without documentation, Chinese asylum seekers have better odds of success than many of the other migrants making the dangerous journey north.

An estimated 55% of Chinese asylum seekers are successful in making their claims, often citing political oppression and lack of religious freedom in China as motivations. By contrast, only 29% of Venezuelans seeking asylum in the U.S. have their claim granted, and the number is even lower for Colombians, at 19%.

The new halt on the migratory highway from the south has affected thousands of new migrants seeking refuge in the U.S. But the mix of push factors from their home country and encouragement on social media means that Chinese migrants will continue to seek routes to America.

And with both migration and the perceived threat from China likely to be features of the upcoming U.S. election, there is a risk that increased Chinese migration could become politicized, leaning further into existing tensions between Washington and Beijing.

Meredith Oyen does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Read More

Continue Reading

Spread & Containment

Vaccine-skeptical mothers say bad health care experiences made them distrust the medical system

Vaccine skepticism, and the broader medical mistrust and far-reaching anxieties it reflects, is not just a fringe position in the 21st century.

Women's own negative medical experiences influence their vaccine decisions for their kids. AP Photo/Ted S. Warren

Why would a mother reject safe, potentially lifesaving vaccines for her child?

Popular writing on vaccine skepticism often denigrates white and middle-class mothers who reject some or all recommended vaccines as hysterical, misinformed, zealous or ignorant. Mainstream media and medical providers increasingly dismiss vaccine refusal as a hallmark of American fringe ideology, far-right radicalization or anti-intellectualism.

But vaccine skepticism, and the broader medical mistrust and far-reaching anxieties it reflects, is not just a fringe position.

Pediatric vaccination rates had already fallen sharply before the COVID-19 pandemic, ushering in the return of measles, mumps and chickenpox to the U.S. in 2019. Four years after the pandemic’s onset, a growing number of Americans doubt the safety, efficacy and necessity of routine vaccines. Childhood vaccination rates have declined substantially across the U.S., which public health officials attribute to a “spillover” effect from pandemic-related vaccine skepticism and blame for the recent measles outbreak. Almost half of American mothers rated the risk of side effects from the MMR vaccine as medium or high in a 2023 survey by Pew Research.

Recommended vaccines go through rigorous testing and evaluation, and the most infamous charges of vaccine-induced injury have been thoroughly debunked. How do so many mothers – primary caregivers and health care decision-makers for their families – become wary of U.S. health care and one of its most proven preventive technologies?

I’m a cultural anthropologist who studies the ways feelings and beliefs circulate in American society. To investigate what’s behind mothers’ vaccine skepticism, I interviewed vaccine-skeptical mothers about their perceptions of existing and novel vaccines. What they told me complicates sweeping and overly simplified portrayals of their misgivings by pointing to the U.S. health care system itself. The medical system’s failures and harms against women gave rise to their pervasive vaccine skepticism and generalized medical mistrust.

The seeds of women’s skepticism

I conducted this ethnographic research in Oregon from 2020 to 2021 with predominantly white mothers between the ages of 25 and 60. My findings reveal new insights about the origins of vaccine skepticism among this demographic. These women traced their distrust of vaccines, and of U.S. health care more generally, to ongoing and repeated instances of medical harm they experienced from childhood through childbirth.

girl sitting on exam table faces a doctor viewer can see from behind
A woman’s own childhood mistreatment by a doctor can shape her health care decisions for the next generation. FatCamera/E+ via Getty Images

As young girls in medical offices, they were touched without consent, yelled at, disbelieved or threatened. One mother, Susan, recalled her pediatrician abruptly lying her down and performing a rectal exam without her consent at the age of 12. Another mother, Luna, shared how a pediatrician once threatened to have her institutionalized when she voiced anxiety at a routine physical.

As women giving birth, they often felt managed, pressured or discounted. One mother, Meryl, told me, “I felt like I was coerced under distress into Pitocin and induction” during labor. Another mother, Hallie, shared, “I really battled with my provider” throughout the childbirth experience.

Together with the convoluted bureaucracy of for-profit health care, experiences of medical harm contributed to “one million little touch points of information,” in one mother’s phrase, that underscored the untrustworthiness and harmful effects of U.S. health care writ large.

A system that doesn’t serve them

Many mothers I interviewed rejected the premise that public health entities such as the Centers for Disease Control and Prevention and the Food and Drug Administration had their children’s best interests at heart. Instead, they tied childhood vaccination and the more recent development of COVID-19 vaccines to a bloated pharmaceutical industry and for-profit health care model. As one mother explained, “The FDA is not looking out for our health. They’re looking out for their wealth.”

After ongoing negative medical encounters, the women I interviewed lost trust not only in providers but the medical system. Frustrating experiences prompted them to “do their own research” in the name of bodily autonomy. Such research often included books, articles and podcasts deeply critical of vaccines, public health care and drug companies.

These materials, which have proliferated since 2020, cast light on past vaccine trials gone awry, broader histories of medical harm and abuse, the rapid growth of the recommended vaccine schedule in the late 20th century and the massive profits reaped from drug development and for-profit health care. They confirmed and hardened women’s suspicions about U.S. health care.

hands point to a handwritten vaccination record
The number of recommended childhood vaccines has increased over time. Mike Adaskaveg/MediaNews Group/Boston Herald via Getty Images

The stories these women told me add nuance to existing academic research into vaccine skepticism. Most studies have considered vaccine skepticism among primarily white and middle-class parents to be an outgrowth of today’s neoliberal parenting and intensive mothering. Researchers have theorized vaccine skepticism among white and well-off mothers to be an outcome of consumer health care and its emphasis on individual choice and risk reduction. Other researchers highlight vaccine skepticism as a collective identity that can provide mothers with a sense of belonging.

Seeing medical care as a threat to health

The perceptions mothers shared are far from isolated or fringe, and they are not unreasonable. Rather, they represent a growing population of Americans who hold the pervasive belief that U.S. health care harms more than it helps.

Data suggests that the number of Americans harmed in the course of treatment remains high, with incidents of medical error in the U.S. outnumbering those in peer countries, despite more money being spent per capita on health care. One 2023 study found that diagnostic error, one kind of medical error, accounted for 371,000 deaths and 424,000 permanent disabilities among Americans every year.

Studies reveal particularly high rates of medical error in the treatment of vulnerable communities, including women, people of color, disabled, poor, LGBTQ+ and gender-nonconforming individuals and the elderly. The number of U.S. women who have died because of pregnancy-related causes has increased substantially in recent years, with maternal death rates doubling between 1999 and 2019.

The prevalence of medical harm points to the relevance of philosopher Ivan Illich’s manifesto against the “disease of medical progress.” In his 1982 book “Medical Nemesis,” he insisted that rather than being incidental, harm flows inevitably from the structure of institutionalized and for-profit health care itself. Illich wrote, “The medical establishment has become a major threat to health,” and has created its own “epidemic” of iatrogenic illness – that is, illness caused by a physician or the health care system itself.

Four decades later, medical mistrust among Americans remains alarmingly high. Only 23% of Americans express high confidence in the medical system. The United States ranks 24th out of 29 peer high-income countries for the level of public trust in medical providers.

For people like the mothers I interviewed, who have experienced real or perceived harm at the hands of medical providers; have felt belittled, dismissed or disbelieved in a doctor’s office; or spent countless hours fighting to pay for, understand or use health benefits, skepticism and distrust are rational responses to lived experience. These attitudes do not emerge solely from ignorance, conspiracy thinking, far-right extremism or hysteria, but rather the historical and ongoing harms endemic to the U.S. health care system itself.

Johanna Richlin does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Read More

Continue Reading

Government

Survey Shows Declining Concerns Among Americans About COVID-19

Survey Shows Declining Concerns Among Americans About COVID-19

A new survey reveals that only 20% of Americans view covid-19 as "a major threat"…

Published

on

Survey Shows Declining Concerns Among Americans About COVID-19

A new survey reveals that only 20% of Americans view covid-19 as "a major threat" to the health of the US population - a sharp decline from a high of 67% in July 2020.

(SARMDY/Shutterstock)

What's more, the Pew Research Center survey conducted from Feb. 7 to Feb. 11 showed that just 10% of Americans are concerned that they will  catch the disease and require hospitalization.

"This data represents a low ebb of public concern about the virus that reached its height in the summer and fall of 2020, when as many as two-thirds of Americans viewed COVID-19 as a major threat to public health," reads the report, which was published March 7.

According to the survey, half of the participants understand the significance of researchers and healthcare providers in understanding and treating long COVID - however 27% of participants consider this issue less important, while 22% of Americans are unaware of long COVID.

What's more, while Democrats were far more worried than Republicans in the past, that gap has narrowed significantly.

"In the pandemic’s first year, Democrats were routinely about 40 points more likely than Republicans to view the coronavirus as a major threat to the health of the U.S. population. This gap has waned as overall levels of concern have fallen," reads the report.

More via the Epoch Times;

The survey found that three in ten Democrats under 50 have received an updated COVID-19 vaccine, compared with 66 percent of Democrats ages 65 and older.

Moreover, 66 percent of Democrats ages 65 and older have received the updated COVID-19 vaccine, while only 24 percent of Republicans ages 65 and older have done so.

“This 42-point partisan gap is much wider now than at other points since the start of the outbreak. For instance, in August 2021, 93 percent of older Democrats and 78 percent of older Republicans said they had received all the shots needed to be fully vaccinated (a 15-point gap),” it noted.

COVID-19 No Longer an Emergency

The U.S. Centers for Disease Control and Prevention (CDC) recently issued its updated recommendations for the virus, which no longer require people to stay home for five days after testing positive for COVID-19.

The updated guidance recommends that people who contracted a respiratory virus stay home, and they can resume normal activities when their symptoms improve overall and their fever subsides for 24 hours without medication.

“We still must use the commonsense solutions we know work to protect ourselves and others from serious illness from respiratory viruses, this includes vaccination, treatment, and staying home when we get sick,” CDC director Dr. Mandy Cohen said in a statement.

The CDC said that while the virus remains a threat, it is now less likely to cause severe illness because of widespread immunity and improved tools to prevent and treat the disease.

Importantly, states and countries that have already adjusted recommended isolation times have not seen increased hospitalizations or deaths related to COVID-19,” it stated.

The federal government suspended its free at-home COVID-19 test program on March 8, according to a website set up by the government, following a decrease in COVID-19-related hospitalizations.

According to the CDC, hospitalization rates for COVID-19 and influenza diseases remain “elevated” but are decreasing in some parts of the United States.

Tyler Durden Sun, 03/10/2024 - 22:45

Read More

Continue Reading

Trending